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Sir, multiple observers are a reality of large observational and multicentre studies and 
introduce the challenge of addressing inter-rater reliability. Long term Outcomes in 
Psoriatic ArthritiS II (LOPAS II) is a multicentre prospective observational study 
investigating Work Disability (WD) in Psoriatic Arthritis (PsA). The primary endpoint is 
presenteeism (reduced effectiveness at work) but the secondary endpoints include 
tender and swollen joint scores. Clinical assessments will be undertaken at multiple 
sites across the UK. We set out to undertake a reliability exercise to estimate joint 
count reliability in LOPAS II. 
 
We invited assessors from each centre to an education day at the lead site. A one 
hour seminar on the study was followed by a forty five minute clinical training session 
on joint counts lead by 2 trainers, each with more than 10 years’ experience in PsA 
joint assessment. The session was followed by a joint count reliability exercise. Four 
patients of differing disease duration (1 to 33yrs) and activity (from 22 tender and 9 
swollen to 2 tender and 2 swollen joints as assessed by the instructors) were 
assessed using a modified (asymmetrical) Latin square design. Reliability was 
measured using the Krippendorff’s alpha, a reliability coefficient that accommodates 
the modified Latin square design1. Analyses were undertaken on the group as a 
whole then repeated excluding those who self-reported to be unconfident or who had 
never performed joint assessments before.  
 
Twelve assessors from seven units attended, one doctor, seven rheumatology nurse 
specialists, one occupational therapist and three research nurses (of whom one had 
rheumatology experience). Reliability is reported in table 1. Inter-rater reliability for all 
was low irrespective of experience but was higher amongst those with experience.  
 
There are limited reports of joint count reliability in PsA 2-5 and these have focused on 
the reliability amongst physicians with an interest in PsA. Even amongst such 
experts, inter class correlation coefficients (ICC) are poor for determining peripheral 
joint swelling 0.13, 0.5 5, 0,24 2 and moderate for tenderness (or ‘activity’), 0.7 3, 0.75, 
0.7 2. It is noteworthy that none of these studies have included the wider 
multidisciplinary team.  
 
To our knowledge, none of the recently published large observational studies or 
registry reports has reported on joint count reliability 6-10. Only the Toronto research 
group has reported on joint count reliability and this was at the time of the cohort’s 
inception 4. The Toronto study involved 3 rheumatologists and 2 trainees assessing 
five patients in a Latin square design. There was a less than 1% observer variance 
indicating good reliability of assessment. To enable direct comparison the analysis of 
variance in our study showed the proportion of variance attributable to (all) raters was 
much higher; swollen joints 56% (p=0.094) and tender joints 60% (p=0.004). It is 
noteworthy that the Toronto study was undertaken over twenty years ago and since 
that time the expansion of the multidisciplinary team has meant that clinical 
assessments are now performed by a wider clinical team including doctors, nurses 
and extended scope therapists. The general lack of reporting of joint count reliability 
may reflect a mixture of publication bias, insufficient recognition of the potential 
problem or misplaced confidence. The poor reliability identified in our study is 
important to our current study (LOPAS II) but also to assessors from centres in the 
United Kingdom (UK) and further afield who collect data for other large observational 
studies in PsA.  
 
The joint count training offered in the LOPAS II training day was minimal as we had 
only anticipated the need for some ‘fine tuning’ to standardise the assessment 
techniques. More training is required as was mentioned by the assessors themselves 
in the feedback from the training day.  We are attempting to standardise 
assessments and improve our reliability by using an instructional joint count training 
video as well as offering one to one tuition at the lead site. We are also encouraging 
a period of mentoring within each unit for those with less experience as well as 
aiming to use the same assessor to perform the joint counts at serial appointments. 
 
To our knowledge this is the first study investigating the joint count reliability amongst 
assessors routinely contributing data in the PsA clinical and research setting. We 
suggest future reporting of joint count outcomes should include some assessment of 
joint count reliability in order to interpret results, particularly negative findings. 
Furthermore we suggest that to optimise data collection, individual units document 
joint count reliability with a view to determining a potential training need.  
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